612-345-4544 info@brightresearchpartners.com
BRIGHT Research Partners
  • HOME
  • BACKSTORY
  • OUR VALUES
  • IDEAL CLIENTS
  • THE TEAM
  • BRIGHT INSIGHTS
  • CONNECT
Select Page
Regulatory Pathway Defines the Need for a Clinical Study

Regulatory Pathway Defines the Need for a Clinical Study

by Lisa Gallatin, RAC, Director of Regulatory and Quality | May 11, 2021 | ClinReg Strategy

You are developing a medical device that addresses a clinical need, but how do you get it into the hands of physicians to improve the lives of patients? In this article, we discuss the most common FDA pathways to market clearance and share a few insights to help you...
5 Tips to Execute a Successful FDA Pre-Sub Meeting for Your Clinical Study

5 Tips to Execute a Successful FDA Pre-Sub Meeting for Your Clinical Study

by Lisa Gallatin, RAC, Director of Regulatory and Quality | Apr 6, 2021 | ClinReg Strategy

The voluntary FDA Q-Submission Program, specifically the pre-sub meeting process, can serve as a powerful tool to streamline and optimize your medical device product development strategies, timelines, and budget, especially if you need to conduct a clinical study. In...
5 Tips to Prepare for a Successful FDA Pre-Sub Meeting for Your Clinical Study

5 Tips to Prepare for a Successful FDA Pre-Sub Meeting for Your Clinical Study

by Lisa Gallatin, RAC, Director of Regulatory and Quality | Mar 25, 2021 | ClinReg Strategy

The medical device product development cycle can take several years and cost millions of dollars, especially when a clinical study is required. With an investment that large, it’s smart strategy to ensure your study design is locked-in well before you submit an...

Categories

  • BRIGHT Culture (5)
  • ClinReg Strategy (5)
  • Data Management (4)
  • Monitoring (2)
  • Study Execution (9)
©2021 All Rights Reserved BRIGHT Research Partners, Inc. | View our Privacy Policy | This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.